deltatrials
Recruiting PHASE2 INTERVENTIONAL 1-arm NCT05969496

Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Inferior Vena Cava Tumor Thrombus (NEOPAX)

Neoadjuvant Pembrolizumab and Axitinib in Renal Cell Carcinoma With Associated Inferior Vena Cava Tumor Thrombus (NEOPAX)

Sponsor: Cancer League of Colorado

Conditions Inferior Vena Cava Thrombosis Kidney Cancer Renal Cancer Renal Cell Carcinoma
Interventions Axitinib Pembrolizumab
Updated 8 times since 2023 Last updated: Apr 1, 2025 Started: Dec 4, 2023 Primary completion: Nov 1, 2026 Completion: Nov 30, 2029
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Inferior Vena Cava Thrombosis and Kidney Cancer and is currently actively recruiting participants. Cancer League of Colorado leads this study, which shows 8 recorded versions since 2023 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Dec 2023 · 2 months · monthly snapshot~Dec 2023 – ~Feb 2024 · 2 months · monthly snapshot~Feb 2024 – ~Jul 2024 · 5 months · monthly snapshotRecruiting~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Nov 2024 · 2 months · monthly snapshot~Nov 2024 – ~May 2025 · 6 months · monthly snapshotRecruiting~May 2025 – present · 15 months · monthly snapshotRecruiting

Change History

8 versions recorded

  1. May 2025 — Present [monthly]

    Recruiting PHASE2

  2. Nov 2024 — May 2025 [monthly]

    Recruiting PHASE2

  3. Sep 2024 — Nov 2024 [monthly]

    Recruiting PHASE2

  4. Jul 2024 — Sep 2024 [monthly]

    Recruiting PHASE2

  5. Feb 2024 — Jul 2024 [monthly]

    Recruiting PHASE2

▶ Show 3 earlier versions

  1. Dec 2023 — Feb 2024 [monthly]

    Recruiting PHASE2

  2. Oct 2023 — Dec 2023 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  3. Sep 2023 — Oct 2023 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Cancer League of Colorado
  • University of Colorado, Denver
Data source: University of Colorado, Denver

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations